DÄ internationalArchive51-52/2006The Place of Neuraminidase Inhibitors in the Prophylaxis and Treatment of Influenza

Review article

The Place of Neuraminidase Inhibitors in the Prophylaxis and Treatment of Influenza

Dtsch Arztebl 2006; 103(51-52): A-3486

Tröger, U; Bode-Böger, S M

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

1. Nationaler Influenzapandemieplan Teil 2. Bundesgesundheitsblatt – Gesundheitsforschung – Gesundheitsschutz 48/3 2005 [März 2005], Stand Juli 2005
2. Moscona A: Neuraminidase inhibitors for influenza. N Engl J Med 2005; 353: 1363–73. MEDLINE
3. Ohuchi M, Asaoka N, Sakai T, Ohuchi R: Roles of neuraminidase in the initial stage of influenza virus infection. Microbes Infect. 2006; 8: 1287–93. MEDLINE
4. He G, Massarella J, Ward P: Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 1999; 37: 471–84. MEDLINE
5. Shi D, Yang J, Yang D et al.: Anti-influenza viral prodrug oseltamivir is activated by carboxylesterase HCE1 and the activation is inhibited by anti-platelet agent clopidogrel. J Pharmacol Exp Ther 2006; 319; 1477–84. MEDLINE
6. Cooper NJ, Sutton AJ, Abrams KR et.: Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 2003; 326: 1235. MEDLINE
7. Johnston SL, Ferrero F, Garcia ML, Dutkowski R: Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma. Pediatr Infect Dis J 2005; 24: 225–32. MEDLINE
8. Whitley RJ, Hayden FG, Reisinger KS et al.: Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20: 127–33. MEDLINE
9. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F: Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003; 163: 1667–72. MEDLINE
10. Monto AS, Webster A, Keene O: Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza a and b: pooled efficacy analysis. J Antimicrobial Chemother 1999; 44: 23–9. MEDLINE
11. Lalezari J, Camion K, Keene O, Silagy C: Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Arch Intern Med 2001; 161: 212–7. MEDLINE
12. Tran TH, Nguyen TL, Nguyen TD et al.: World Health Organization International Avian Influenza Investigative Team. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 2004; 350: 1179–88. MEDLINE
13. Welliver R, Monto AS, Carewicz O et al.: Oseltamivir Post Exposure Prophylaxis Investigator Group. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001; 285: 748–54. MEDLINE
14. Hayden FG, Atmar RL, Schilling M et al.: Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999; 341: 1336–43. MEDLINE
15. Peters PH Jr, Gravenstein S, Norwood P et al.: Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc 2001; 49: 1025–31. MEDLINE
16. Monto AS, Pichichero ME, Blanckenberg SJ et al.: Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis 2002; 186: 1582–8. MEDLINE
17. Kaiser L, Henry D, Flack NP, Keene O, Hayden FG: Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study. Clin Infect Dis 2000; 30: 587–9. MEDLINE
18. Hayden FG, Gubareva LV, Monto AS et al.: Zanamivir Family Study Group. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. N Engl J Med 2000; 343: 1282–9. MEDLINE
19. Kiso M, Mitamura K, Sakai-Tagawa Y et al.: Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004; 364: 759–65. MEDLINE
20. Le QM, Kiso M, Someya K et al.: Avian Flu. Isolation of drug-resistant H5N1 virus. Nature 2005; 437: 1108. MEDLINE
21. de Jong MD, Tran TT, Truong HK et al.: Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005; 353: 2667–72. MEDLINE
22. Moscona A: Oseltamivir Resistance – Disabling Our Influenza Defenses. N Engl J Med 2005; 353; 2233–6. MEDLINE
23. Treanor JJ, Hayden FG, Vrooman PS et al.: Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283: 1016–24. MEDLINE
24. Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A: Antivirals for influenza in healthy adults: systematic review. Lancet. 2006; 367: 303–13. MEDLINE
25. Cole A: Experts question wisdom of stockpiling oseltamivir. BMJ 2005; 331: 1041. MEDLINE
e1. www.who.int/csr/resources/publications/influenza
e2. Enserink M.: Epidemiology. A drug makes it big-but can it deliver? Science 2005; 309: 871. MEDLINE
e3. Cass LM, Efthymiopoulos C, Bye A: Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet 1999; 36 Suppl. 1: 1–11. MEDLINE
e4. Fachinformation zu Tamiflu (Stand 02/2005).
e5. Fachinformation zu Relenza (Stand 02/2005).
e6. N.N.: Neuraminidase Inhibitor Susceptibility Network: Use of influenza antivirals during 2003-2004 and monitoring of neuraminidase inhibitor resistance. Wkly Epidemiol Rec 2005; 80: 156. MEDLINE
e7. Bekanntgaben der Herausgeber: Kassenärztliche Bundesvereinigung – Bundes­ärzte­kammer. Mitteilungen: Saisonale Influenza, Vogelgrippe und potenzielle Influenzapandemie. Dtsch Arztebl 2005; 102(49): A 3444–55. VOLLTEXT
e8. Jefferson T, Demicheli V, Di Pietrantonj C, Jones M, Rivetti D: Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst Rev 2006; 3: CD001265. MEDLINE